Urol. praxi. 2019;20(2):62-65 | DOI: 10.36290/uro.2019.051

The role of ARTAs in treating metastatic castration-resistant prostate cancer

MUDr. PharmDr. Jan Dvořák
Radioterapeutická a onkologická klinika FNKV, 3. LF UK Praha, 1. LF UK Praha

The article deals with the role of ARTAs, particularly in treating metastatic castration-resistant prostate cancer, presenting available
data and their utilization in practical treatment-related decision making.

Keywords: metastatic castration-resistant prostate cancer mCRPCa, ARTA, chemotherapy, chemonaive, prechemotherapy indication,postchemotherapy indication

Published: May 17, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dvořák J. The role of ARTAs in treating metastatic castration-resistant prostate cancer. Urol. praxi. 2019;20(2):62-65. doi: 10.36290/uro.2019.051.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Scher HI, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2008; 26(7): 1148.
    2. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer. 2009; 45(2): 228-247. Go to original source... Go to PubMed...
    3. Tannock IF, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine, 2004; 351(15): 1502-1512. Go to original source... Go to PubMed...
    4. Berthold DR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. Journal of Clinical Oncology 2008; 26(2): 242-245. Go to original source... Go to PubMed...
    5. De Bono JS, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet, 2010; 376(9747): 1147-1154. Go to original source... Go to PubMed...
    6. De Bono JS, et al. Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine, 2011; 364(21): 1995-2005. Go to original source... Go to PubMed...
    7. Fizazi K, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncol 2012; 13: 983-992. Go to original source... Go to PubMed...
    8. Scher HI, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine, 2012; 367(13): 1187-1197. Go to original source... Go to PubMed...
    9. Ryan ChJ, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine, 2013; 368(2): 138-148. Go to original source... Go to PubMed...
    10. Ryan ChJ, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology, 2015; 16(2): 152-160. Go to original source... Go to PubMed...
    11. Miller K, et al. EAU 31 Annual EAU congres Munich 2016, poster 775.
    12. Beer TM, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. New England Journal of Medicine, 2014; 371(5): 424-433. Go to original source... Go to PubMed...
    13. Beer TM, et al. Enzalutamide in Men with Chemotherapy-na?ve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol 2017; 71: 151-154. Go to original source... Go to PubMed...
    14. Van Soest R, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015; 67: 981-985. Go to original source... Go to PubMed...
    15. Smith MR, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. New England Journal of Medicine, 2018; 378(15): 1408-1418. Go to original source... Go to PubMed...
    16. Husain M, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. New England Journal of Medicine, 2018; 378(26): 2465-2474. Go to original source... Go to PubMed...
    17. Fizazi K, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2019. Go to original source... Go to PubMed...
    18. Fizazi K, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine, 2017; 377(4): 352-360. Go to original source... Go to PubMed...
    19. James ND, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine, 2017; 377(4): 338-351. Go to original source... Go to PubMed...
    20. Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI(R) (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer. Astellas Pharma Inc. Published December 20, 2018. https://prn.to/2SaGyR5?rel=0". Accessed December 20, 2018.
    21. Janssen Announces ERLEADA(R)(apalutamide) Phase 3 TITAN Study Unblinded as Dual Primary Endpoints Achieved in Clinical Program Evaluating Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer Phase 3 Study Unblinded Following Recommendation of Independent Data Monitoring Committee. Spring House, PA, January 30, 2019.
    22. Hideaki M, et al. Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy Na?ve Metastatic Castration-Resistant Prostate Cancer Clinical. Genitourinary Cancer, 2017; 15(4): 591-597. Go to original source... Go to PubMed...
    23. Sonpavde G, et al. After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices. Clinical Genitourinary Cancer 2015; 13(4): 309-318. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.